These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1698740)

  • 1. Interleukin-1 abrogates anterior chamber-associated immune deviation.
    Benson JL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2123-8. PubMed ID: 1698740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation.
    Niederkorn JY
    Transplantation; 1987 Apr; 43(4):523-8. PubMed ID: 2953091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID.
    Wilbanks GA; Mammolenti M; Streilein JW
    J Immunol; 1991 May; 146(9):3018-24. PubMed ID: 2016537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
    Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
    Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation.
    Kawashima H; Yamagami S; Tsuru T; Gregerson DS
    Eur J Immunol; 1997 Oct; 27(10):2490-4. PubMed ID: 9368601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of splenic B cells in the immune privilege of the anterior chamber of the eye.
    Niederkorn JY; Mayhew E
    Eur J Immunol; 1995 Oct; 25(10):2783-7. PubMed ID: 7589072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood.
    Wilbanks GA; Streilein JW
    J Immunol; 1991 Apr; 146(8):2610-7. PubMed ID: 1707912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
    Niederkorn JY; Streilein JW
    J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
    Yamada J; Zhu SN; Streilein JW; Dana MR
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel role for TGF-beta and IL-10 in the induction of immune privilege.
    D'Orazio TJ; Niederkorn JY
    J Immunol; 1998 Mar; 160(5):2089-98. PubMed ID: 9498745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation.
    Ferguson TA; Herndon JM; Dube P
    Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2643-51. PubMed ID: 8163352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta.
    Wilbanks GA; Mammolenti M; Streilein JW
    Eur J Immunol; 1992 Jan; 22(1):165-73. PubMed ID: 1530916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma allografts abrogate immune privilege within the anterior chamber of the eye.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1235-43. PubMed ID: 3089965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege.
    Dana MR; Dai R; Zhu S; Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):70-7. PubMed ID: 9430547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells.
    Chattopadhyay S; O'Rourke J; Cone RE
    Int Immunol; 2008 Apr; 20(4):509-16. PubMed ID: 18359787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic restrictions and cellular interactions in the induction of anterior chamber associated immune deviation (ACAID).
    Ferguson TA; Kaplan HJ
    Reg Immunol; 1988; 1(1):62-8. PubMed ID: 2978943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber.
    Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2833-43. PubMed ID: 9418737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.